BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Branham Law Group, LLP Investigating Zeltiq for Possible Fiduciary Duty Breaches by Officers and Directors


3/26/2012 9:40:58 AM

DALLAS, Mar 25, 2012 /PRNewswire/ -- Branham Law Group, LLP is investigating potential securities law violations by certain officers and/or directors of ZELTIQ Aesthetics, Inc., Nasdaq ZLTQ ("ZELTIQ"). Whether certain statements issued by ZELTIQ were false and misleading is the focus of the investigation. The primary focus is on certain statements issued between October 18, 2011 and March 6, 2012, regarding ZELTIQ's business, operations and financial condition.

ZELTIQ shareholders who purchased shares between October 18, 2011 and March 6, 2012 should contact Trey Branham at 855-722-5910 or at tbranham@branhamlawgroup.com to learn more about this investigation.

ZELTIQ is a medical technology corporation. Specifically, ZELTIQ focuses on the development and sales of fat reducing products. On March 6, 2012 ZELTIQ announced that it lost $5.8 million, or $0.22 per share, in the fourth fiscal quarter. Moreover, ZELTIQ substantially lowered its guidance forecast. Immediately after this acknowledgment, the ZELTIQ shares declined $3.75 per share, or 33.75%, closing at $7.36 per share on March 6, 2012.

If you hold ZELTIQ shares and held them during the above period and have information about or questions concerning these issues or your rights as a shareholder, you may contact Trey Branham at 855-722-5910 or tbranham@branhamlawgroup.com.

Damaged ZELTIQ shareholders have the option of filing a class action lawsuit to recover damages incurred as a result of disclosures.

The Branham Law Group, LLP has extensive experience in securities and commercial litigation and handled claims of investor fraud, partnership oppression, shareholder derivative suits, and class actions of all types. The Branham Law Group also advises whistleblowers on appropriate courses of actions.

SOURCE Branham Law Group, LLP



Read at BioSpace.com

Zeltiq
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->